Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis

Journal of Neurology

Volumn 259, Issue 6, 2012, Pages 1215-1221

  Melin, A ^a   Outteryck, O ^a   Collongues, N ^b   Zephir H ^a   Fleury, M C ^b   Blanc, F ^b   Lacour, A ^a   Ongagna, J C ^b   Berteloot, A S ^a   Vermersch, P ^a   De Seze J ^b  

^a UNIV LILLE   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Disease activity free; MRI; Multiple sclerosis; Natalizumab

Indexed keywords

GADOLINIUM; NATALIZUMAB;

ADULT; ARTICLE; BRAIN RADIOGRAPHY; CLINICAL PRACTICE; COHORT ANALYSIS; CONTRAST ENHANCEMENT; COURSE EVALUATION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; POST HOC ANALYSIS; PRIORITY JOURNAL; RELAPSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862765220     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6339-8     Document Type: Article

References (10)

1. CH Polman PW O'Connor E Havrdova, et al. 2006 A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899 910 16510744 10.1056/NEJMoa044397 1:CAS:528:DC%2BD28XitVertL4%3D
2. E Havrdova S Galetta M Hutchinson, et al. 2009 Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study Lancet Neurol 8 254 260 19201654 10.1016/S1474-4422(09)70021-3
3. PA Calabresi G Giovannoni C Confavreux, et al. 2007 The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL Neurology 69 1391 1403 17761550 10.1212/01.wnl.0000277457.17420.b5 1:CAS:528:DC%2BD2sXhtVyntbzI
4. L Prosperini G Borriello F Fubelli, et al. 2010 Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome Neurol Sci 31 Suppl 3 S303 S307
5. O Fernandez O Papais Alvarenga M Guerrero, et al. 2011 The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study Mult Scler 17 192 197 21088044 10.1177/1352458510385507
6. GL Mancardi G Tedeschi MP Amato, et al. 2011 Three years of experience: the Italian registry and safety data update Neurol Sci 31 Suppl 3 S295 S297 10.1007/s10072-010-0356-8
7. F Piehl C Holmen J Hillert, et al. 2011 Swedish natalizumab (Tysabri) multiple sclerosis surveillance study Neurol Sci 31 Suppl 3 S289 S293 10.1007/s10072-010-0345-y
8. F Sangalli L Moiola S Bucello, et al. 2011 Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post marketing observational study Neurol Sci 31 Suppl 3 S299 S302 10.1007/s10072-010-0344-z
9. C Holmen F Piehl J Hillert, et al. 2011 A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis Mult Scler 17 708 719 21228027 10.1177/1352458510394701
10. M Hutchinson L Kappos PA Calabresi, et al. 2009 The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL J Neurol 256 405 415 19308305 10.1007/s00415-009-0093-1 1:CAS:528:DC%2BD1MXltlKrs78%3D